NCOA3 and breast cancer: Similarly, in a study by Qiao et al.15on breast cancer, NR5A2 acted synergistically with NCOA3 and attenuated the process of mastocytosis via the upregulation of NRF2, which in turn induced resistance to BET inhibitors (BETi); however, the use of a small‐molecule inhibitor of NR5A2 enhanced the activity of BETi both in vivo and in vitro, thereby enhancing its anticancer effects in breast cancer cells.